ORIC Q3 2024 Earnings — ORIC Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ORICORIC Pharmaceuticals, Inc.

$1B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$38M

Net Income

-$35M

EPS (Diluted)

$-0.49

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$29M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$302M

Total Liabilities

$28M

Stockholders' Equity

$274M

Cash & Equivalents

$44M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$38M	-$29M	-33.6%
Net Income	-$35M	-$25M	-35.7%